ACUTE LEUKEMIAS &MYELOPROLIFERATIVE NEOPLASMS

WESTIN AT LAS COLINAS | DALLAS, TX

Expert Forum on

FEB 28-29,2020

RICHARD STONE, MD Harvard Medical School

Dana-Farber Cancer InstituteBoston, MA

EUNICE WANG, MDChief, Leukemia Service

Roswell Park Cancer InstituteBuffalo, NY

CHAIRS

FEB 28-29, 2020 | DALLAS, TX

Expert Forum onACUTE LEUKEMIAS & MYELOPROLIFERATIVE NEOPLASMS

FACULTY

PRITHVIRAJ BOSE, MDAssociate Professor of MedicineUT MD Anderson Cancer CenterHouston, TX

SHENG CAI, MD, PHDAssistant AttendingMemorial Sloan Kettering Cancer CenterNew York, NY

NAVAL DAVER, MDAssociate ProfessorUT MD Anderson Cancer CenterHouston, TX

H. JOACHIM DEEG, MDMember, Clinical Research DivisionFred Hutchinson Cancer Research CenterSeattle, WA

TODD DRULEY, MD, PHDChief Medical OfficerArcherDX, Inc. Boulder, CO

ELIHU H. ESTEY, MD Professor, Division of Hematology, University of Washington School of Medicine (UW)Member Clinical Research Division Fred Hutchinson Cancer Research Center (FHCRC)Director of AML Clinical Research UW and FHCRCSeattle, WA

GUILLERMO GARCIA-MANERO, MDDeputy Chair, Translational Medicine UT MD Anderson Cancer CenterHouston, TX

AARON GOLDBERG, MD, PHDAssistant Attending Physician, Leukemia ServiceMemorial Sloan Kettering Cancer CenterNew York, NY

MARINA KONOPLEVA, MD, PHDProfessorUT MD Anderson Cancer CenterHouston, TX

MARK LEVIS, MD, PHDProfessor of Oncology Johns Hopkins School of MedicineBaltimore, MD

MARK LITZOW, MDHead, Acute Leukemia GroupMayo ClinicRochester, MN

ROBERT MARTELL, MD, PHDHead of Research and DevelopmentCuris, Inc.Lexington, MA

JOHN MASCARENHAS, MDAssociate ProfessorMount Sinai School of MedicineNew York, NY

SOHEIL MESHINCHI, MD, PHDProfessor of MedicineFred Hutchinson Cancer CenterSeattle, WA

NAVEEN PEMMARAJU, MDAssociate ProfessorUT MD Anderson Cancer CenterHouston, TX

KEITH PRATZ, MDDirector of Leukemia ProgramAssociate Professor of MedicineUniversity of PennsylvaniaPhiladelphia, PA

JERRY RADICH, MDProfessorFred Hutchinson Cancer CenterSeattle, WA

FARHAD RAVANDI, MDJaniece and Stephen A. Lasher Professor of MedicineUT MD Anderson Cancer CenterHouston, TX

DAVID RIZZIERI, MDProfessor of Medicine Duke Cancer InstituteDurham, NC

DAVID ROTH, MDChief Medical Officer Syros PharmaceuticalsCambridge, MA

RICHARD STONE, MD CHAIRProfessor of MedicineHarvard Medical SchoolDirector, Translational ResearchAdult Leukemia ProgramDana-Farber Cancer InstituteBoston, MA

KOICHI TAKAHASHI, MDAssistant ProfessorUT MD Anderson Cancer CenterHouston, TX

JEFFREY TYNER, PHDProfessor of MedicineOregon Health Sciences UniversityPortland, OR

EUNICE WANG, MD CHAIRChief, Leukemia ServiceRoswell Park Cancer InstituteBuffalo, NY

NIDIA P. ZAPATA-CANTO, MDHematologyInstituto Nacional de CacnerolgiaMexico City, Mexico

JOSHUA ZEIDNER, MDAssistant Professor of MedicineUNC-Chapel HillChapel Hill, NC

FEB 28-29, 2020 | DALLAS, TX

Expert Forum onACUTE LEUKEMIAS & MYELOPROLIFERATIVE NEOPLASMS

Saturday, February 29, 20206:30 am BREAKFAST

Future of Clinical Trials

Moderator: Elihu Estey

7:30 am What is the Right Design for AML Trials in 2020/2021?

Mark Levis

7:45 am Impact of Exclusion Criteria on AML Patients

Elihu Estey

7:55 am Key Challenges for International Clinical Trials: The Experience in Mexico

Nidia Zapata

8:05 am Incorporating New Prognostic Scores in MDS into Clinical Trials

Guillermo Garcia-Manero

8:15 am ALL and the Future Development of Targeted Therapies

Mark Litzow

8:25 am DISCUSSION

Emerging Drug Showcases

Moderator: Richard Stone

8:40 am CA-4948: A Specific IRAK4 Inhibitor for AML/MDS with Spliceosome Mutations U2AF1 and SF3B1 that Create Oncogenic IRAK4

Robert Martell

8:50 am SY-1425 Targeting RARa in Genomically-defined AML Patients

David Roth

Targeting BCL2 in Acute Leukemias

Moderator: Eunice Wang

9:00 am Novel Venetoclax-based Combinations with Chemotherapy

Richard Stone

9:10 am New Therapies to Abrogate Venetoclax Resistance in AML

Marina Konopleva

9:20 am DISCUSSION

Future Developments of Approved Drugs

Moderator: Eunice Wang

9:30 am Targeting IDH1/2 in the Mitochondrial Energetic Metabolism

Mark Levis

9:40 am New Combinations with CPX-351 Richard Stone

9:50 am Role of Maintenance Therapy in AML: Lessons Learned from the QUAZAR Trial

Farhad Ravandi

10:00 am DISCUSSION

10:20 am BREAK

Friday, Feburary 28, 2020 4:30 pm Welcome and Introductions

Progress in Understanding the Genetics of AML

Moderator: Jeffrey Tyner

4:40 pm What Have We Learned From the BEAT AML Project?

Jeffrey Tyner

4:50 pm Can Unravelling Clonal Evolution in AML Help Guide Therapy with Today’s Drugs?

Koichi Takahashi

5:00 pm Transcriptome-based Response Prediction in AML

Soheil Meshinchi

5:10 pm A Therapeutic Vulnerability for EVI1-high AML

Sheng Cai

5:20 pm DISCUSSION

Can ‘Omic’ Sciences of Biology of AML Pave the Way for MRD Analysis

Moderator: Eunice Wang

5:50 pm Concepts and Methods to Determine Genetic Heterogeneity and MRD in AML

Jerry Radich

6:00 pm Novel Platform for MRD Analysis in Leukemia: ArcherDX

Todd Druley

6:10 pm Using MRD Results for Clinical Decision Making: A 2020 Perspective

Aaron Goldberg

6:20 pm DISCUSSION

Immunotherapy and New Targets for the Treatment of Acute Leukemias

Moderator: David Rizzieri

6:50 pm Venetoclax-based Combinations with Targeted Agents

Naval Daver

7:00 pm Potential for Targeting Macrophages in AML and CLL

Jeffrey Tyner

7:10 pm MDM2 Inhibitors in AML: Current Trials and Future Directions

Naval Daver

7:20 pm Immune Checkpoint-based Approaches in Acute Leukemias

Joshua Zeidner

7:30 pm Cellular Therapies other than Stem Cell Transplant

David Rizzieri

7:40 pm DISCUSSION

8:20 pm ADJOURN TO RECEPTION

FEB 28-29, 2020 | DALLAS, TX

Expert Forum onACUTE LEUKEMIAS & MYELOPROLIFERATIVE NEOPLASMS

Progress in Understanding and Targeting FLT3

Moderator: Richard Stone

10:30 am Genotype-driven Phenotype in FLT3+ AML: Impact of ITD vs TKD

Richard Stone

10:40 am How is Gilteritinib Being Used Post-approval?

Keith Pratz

10:50 am Correlative Data from Crenolanib-treated FLT3-Positive AML

Eunice Wang

11:00 am Role of Clonal Evolution in Single-agent FLT3i Resistance

Jeffrey Tyner

11:10 am DISCUSSION

11:30 am LUNCH

Therapeutic Challenges of MPN and MDS

Moderator: Naveen Pemmaraju

12:20 pm Ruxolitinib-based Combination Therapies

Prithviraj Bose

12:30 pm What to Do After Ruxolitinib Failure Naveen Pemmaraju

12:40 pm Emerging MPN Targets (BETi, MDM2, and TGFB)

John Mascarenhas

12:50 pm What is Next in MDS: Venetoclax and HMA

Aaron Goldberg

1:00 pm DISCUSSION

Improvements in Chemotherapy and Transplantation

Moderator: Richard Stone

1:20 pm Which Patients are “Fit” or “Unfit” for “Intensive” Induction?

Elihu Estey

1:30 pm Role of Maintenance Therapy after Allogeneic Transplant for Myeloid Malignancies

H. Joachim Deeg

1:40 pm Update on the Phase III International Microtransplant in AML Study

David Rizzieri

1:50 pm DISCUSSION

2:00 pm BREAK

Targeted Therapy Strategies for Acute Leukemias

Moderator: Farhad Ravandi

2:20 pm Bispecifics in Acute Leukemias Farhad Ravandi

2:30 pm Rationale for Sonic Hedgehog Inhibition with Chemotherapy in First-line AML

Eunice Wang

2:40 pm Investigational Role of CDK9 Inhibitors in AML

Joshua Zeidner

2:50 pm Novel Targets for AML (CD47, CD70, and p53)

Eunice Wang

3:00 pm DISCUSSION

Closing: Moving the Field Forward

Moderator: Richard Stone

3:20 pm What is Next for These Promising Agents?

Group Discussion

3:30 pm Optimal AML Trial Designs for 2020/2021

Group Discussion

3:40 pm ADJOURN

O N C O L O G Y M E E T I N G I N N O VAT I O N S

davaonc.com